An Open-Label, Dose-escalation/Expansion, Phase 1 Study of ASP4132, Given Orally to Subjects With Advanced Refractory Solid Tumors and Lymphoma
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 18 Oct 2017
At a glance
- Drugs ASP 4132 (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions
- Sponsors Astellas Pharma
- 12 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 12 May 2017 Planned End Date changed from 1 Jan 2019 to 26 Jan 2018.
- 12 May 2017 Planned primary completion date changed from 1 Jan 2019 to 26 Jan 2018.